ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The following serious adverse reactionsare discussed elsewhere in labeling:Nephrogenic Systemic Fibrosis [see Warnings andPrecautions (5.1)] Hypersensitivity Reactions [see Contraindications(4) and Warnings and Precautions (5.2)] Nephrogenic Systemic Fibrosis [see Warnings andPrecautions (5.1)] Hypersensitivity Reactions [see Contraindications(4) and Warnings and Precautions (5.2)] Most common adverse reactions (incidence >0.2%)in patients who received Vueway are injection site pain, headache,nausea, injection site warmth and coldness, dizziness, and localizedswelling. (6.1)To report SUSPECTED ADVERSE REACTIONScontact Bracco Diagnostics Inc. at 1-800-257-5181 or FDA at 1-800-FDA-1088or www.fda.gov/medwatch.. 6.1 Clinical TrialsExperience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.The safety of Vueway was evaluated in 1,047 patients who received Vueway at doses ranging from 0.025 mmol/kg (one half the recommended dose) to 0.3 mmol/kg (six times the recommended dose). total of 708 patients received the recommended dose of 0.05 mmol/kg. Among patients who received the recommended dose, the average age was 51 years (range years to 88 years) and 56% were female. The ethnic distribution was 79% White, 10% Asian, 7% American Indian or Alaska native, 2% Black, and 2% patients of other or unspecified ethnic groups.Overall, approximately 4.7% of subjects receiving the labeled dose reported one or more adverse reactions.Table lists adverse reactions that occurred in 0.2% of patients who received 0.05 mmol/kg Vueway.Table 1. Adverse Reactions Reported in 0.2% of Patients Receiving Vueway in Clinical TrialsAdverse ReactionVueway 0.05 mmol/kg(n=708)(%)Injection site pain0.7Headache0.7Nausea0.4Injection site warmth0.4Injection site coldness0.3Dizziness0.3Localized swelling0.3Adverse reactions that occurred with frequency <= 0.2% in patients who received 0.05 mmol/kg Vueway included: maculopapular rash, vomiting, worsened renal impairment, feeling hot, pyrexia, oral paresthesia, dysgeusia, diarrhea, pruritus, allergic dermatitis, erythema, injection site paresthesia, Cystatin increase, and blood creatinine increase.Adverse Reactions in Pediatric PatientsOne study with single dose of Vueway (0.05 mmol/kg) was conducted in 80 pediatric patients aged years to 17 years, including 60 patients who underwent central nervous system (CNS) MRI and 20 patients who underwent body MRI. One adverse reaction (maculopapular rash of moderate severity) in one patient (1.3%) was reported in the CNS cohort.

BOXED WARNING SECTION.

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF). Gadolinium-based contrast agents (GBCAs) increasethe risk for NSF among patients with impaired elimination of the drugs.Avoid use of GBCAs in these patients unless the diagnostic informationis essential and not available with non-contrasted MRI or other modalities.NSF may result in fatal or debilitating fibrosis affecting the skin,muscle and internal organs.The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR 30 mL/min/1.73m2), orAcute kidney injury. Screen patients for acute kidney injury and other conditionsthat may reduce renal function. For patients at risk for chronicallyreduced renal function (e.g. age 60 years, hypertension, diabetes),estimate the glomerular filtration rate (GFR) through laboratory testing.For patients at highest risk for NSF, do not exceed therecommended Vueway dose and allow sufficient period of time forelimination of the drug from the body prior to any re-administration [see Warnings and Precautions (5.1)].. The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR 30 mL/min/1.73m2), orAcute kidney injury. Chronic, severe kidney disease (GFR 30 mL/min/1.73m2), or. Acute kidney injury.. Screen patients for acute kidney injury and other conditionsthat may reduce renal function. For patients at risk for chronicallyreduced renal function (e.g. age 60 years, hypertension, diabetes),estimate the glomerular filtration rate (GFR) through laboratory testing.. For patients at highest risk for NSF, do not exceed therecommended Vueway dose and allow sufficient period of time forelimination of the drug from the body prior to any re-administration [see Warnings and Precautions (5.1)].. WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)See full prescribing information for complete boxed warningGadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR <30 mL/min/1.73 m2), orAcute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. (5.1). The risk for NSF appears highest among patients with:Chronic, severe kidney disease (GFR <30 mL/min/1.73 m2), orAcute kidney injury. Chronic, severe kidney disease (GFR <30 mL/min/1.73 m2), or. Acute kidney injury.. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. (5.1).

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Gadopiclenol is paramagnetic molecule (macrocyclic non-ionic complex of gadolinium) that develops magnetic moment when placed in magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues.. 12.2 Pharmacodynamics. In MRI, visualization of normal and pathological tissue depends in part on variations in the radiofrequency signal intensity that occur with:differences in proton densitydifferences of the spin-lattice or longitudinal relaxation times (T1)differences in the spin-spin or transverse relaxation time (T2).When placed in magnetic field (patient in MRI machine), gadopiclenol shortens the T1 and T2 relaxation times in targeted tissues. The extent to which contrast agent can affect the relaxation rate of tissue water (1/T1 or 1/T2) is termed relaxivity (r1 or r2).The relaxivity of GBCAs is presented in Table 3.Table 3. Relaxivity (r1) of GBCAs in Human Plasma/Serum at 1.5 and 37CGadolinium-Chelater1 (L.mmol-1.s-1)Gadobenic acid6.3Gadobutrol5.2Gadodiamide4.3Gadopentetic acid4.1Gadopiclenol12.8Gadoteric acid3.6Gadoteridol4.1Gadoxetic acid6.9Cardiac ElectrophysiologyAt times the recommended dosage in adult patients, gadopiclenol does not prolong the QT interval to any clinically relevant extent.. differences in proton density. differences of the spin-lattice or longitudinal relaxation times (T1). differences in the spin-spin or transverse relaxation time (T2).. 12.3 Pharmacokinetics. The Cmax and AUCinf of gadopiclenol increased proportionally over dosage range from 0.025 mmol/kg to 0.3 mmol/kg (0.5 times to times the recommended dosage). At the recommended dose, the mean (CV%) Cmax and AUCinf were 525 (13%) ug/mL and 569 (18%) ug.h/mL, respectively.DistributionAfter intravenous administration of Vueway, gadopiclenol is distributed in the extracellular fluids.The mean (CV%) volume of distribution of gadopiclenol at steady state is 13 (13%) L.Protein binding of gadopiclenol is <= 1.8% at clinically relevant concentrations.Following GBCA administration, gadolinium is present for months or years in brain, bone, skin, and other organs [see Warnings and Precautions (5.3)]. It is unknown whether the recommended dose of Vueway results in similar or different levels of gadolinium retention relative to those of other approved macrocyclic GBCAs at their recommended doses.EliminationThe mean (CV%) elimination half-life (t1/2) of gadopiclenol is 1.5 (14%) hour.The mean (CV%) total body clearance (CL) and renal clearance (CLr) of gadopiclenol are 100 (9.5%) mL/min and 81 (35%) mL/min, respectively. Metabolism Gadopiclenol is not metabolized. Excretion Gadopiclenol is mainly eliminated through the kidneys by glomerular filtration. Approximately 98% of the dose was recovered in urine within 48 hours after administration.Specific PopulationsNo clinically significant differences in the pharmacokinetics of gadopiclenol were observed based on sex.Pediatric PatientsThe pharmacokinetics of gadopiclenol for pediatric patients (2 to 17 years of age) were within range to those of adults (> 18 years of age) [see Dosage and Administration (2.1)].The pharmacokinetic parameters (median [range]) of gadopiclenol in pediatric patients are presented in Table 4.Table 4. Pharmacokinetic Parameters (Median [Range])a According to Age ClassesaAt the recommended dosage2-6 years7-11 years12-17 years>18 yearsCL (L/h/kg)0.12 [0.05; 0.28]0.10 [0.04; 0.24]0.08 [0.04; 0.20]0.08 [0.05; 0.14]t1/2 (h)1.29 [0.69; 3.38]1.48 [0.83; 3.20]1.77 [1.00; 3.57]1.82 [0.93; 3.68]AUCinf (ugoh/mL)403 [169; 964]478 [183; 1077]582 [267; 12901]590 [353; 937]C20 (ug/mL)236 [136; 387]260 [151; 401]286 [155; 441]296 [166; 485]Patients with Renal ImpairmentThe pharmacokinetic parameters (mean (%CV)) of gadopiclenol in patients with renal impairment are presented in Table 5.Table 5. Effect of Renal Impairment on the Pharmacokinetics of Gadopiclenola,b aFollowing administration of single gadopiclenol 0.1 mmol/kg dose (2 times the recommended dosage).beGFR: estimate of GFR based on an estimation equation and expressed in mL/min. To convert mL/min/1.73 m2 to mL/min, multiply by the individuals BSA and divide by 1.73.Normal (eGFR >= 90 mL/min)Mild (eGFR 60 to 90 mL/min)Moderate (eGFR 30 to 60 mL/min)Severe (eGFR 15 to 30 mL/min)AUCinf (ugoh/mL)1113 (24%)1711 (31%)2759 (28%)9671 (18%)CLr (mL/min)96 (10%)76 (23%)44 (25%)14 (26%)t1/2 (h)1.93.33.811.7In patients with mild or moderate renal impairment, more than 90% of the administered Vueway was recovered in urine within 48 hours. In patients with severely impaired renal function about 84% of the administered Vueway was recovered in urine within days.In patients with eGFR 15 mL/min, hemodialysis effectively removed gadopiclenol from plasma as the percentage of decrease in blood concentrations was 95 to 98% at the end of the first hemodialysis session and 100% after the third hemodialysis session [see Warnings and Precautions (5.1), Use in Specific Populations (8.6)].

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. 14.1 Overview of ClinicalStudies. The safety and effectiveness of Vueway for lesion visualization were evaluated in two prospective, double blind, randomized, crossover clinical studies. Study (NCT03996447) was performed in adults with known or highly suspected CNS lesions with focal areas of disruption of the blood-brain barrier. Study (NCT03986138) was performed in adults with suspected enhancing abnormalities in at least one body region among the head and neck, thorax, abdomen, pelvis, and musculoskeletal system.In each study, patients received both Vueway 0.05 mmol/kg and gadobutrol 0.1 mmol/kg (as an active comparator) in random order separated by days to 14 days. Magnetic resonance imaging was performed before and after administration of each contrast agent.Pre-contrast and paired (consisting of both pre-contrast and post-contrast images for the same drug) image sets were independently evaluated by three central readers who were blinded to identity of the contrast agent. Readers scored up to three lesions per patient for border delineation, internal morphology, and contrast enhancement, each on scale from to 4. The total number of lesions was also reported. An additional independent central reader performed lesion tracking to allow matching of lesions between pre-contrast and paired images.The analysis compared the patient-level average score for matching lesions for each visualization parameter between pre-contrast and paired image sets.. 14.2 Visualization of CNS Lesions. Study included 256 patients with known or highly suspected CNS lesion(s). Among the enrolled patients, 239 had assessable pre-contrast and paired images with at least one matching lesion for at least one reader. These patients had mean age of 57 years (range: 18 years to 84 years), 52% were female, and 83% were White.All three blinded readers evaluations of paired pre-contrast plus post-contrast images and pre-contrast images alone for all lesion visualization criteria, the pre-specified co-primary efficacy endpoints, are presented in Table 6.Table 6. Patient-Level CNS Lesion Visualization Scores by Reader, Paired vs. Pre-contrast in Patients Receiving Vueway 0.05 mmol/kg IntravenouslyLS: Least Squares; SE: Standard Error; CI: Confidence Interval.Only matching lesions are considered. The mixed models based on the full analysis set (N=239) include lesion visualization factor as dependent variable, MRI modality (Pre-contrast and Paired MRI) as fixed factors, and patient as random factor.p<0.0001 for all rowsnLS Mean (SE)95% CI differencePairedPreDifferenceBorder delineationReader 12273.90 (0.02)2.08 (0.02)1.82 (0.03)(1.76, 1.88)Reader 22293.64 (0.04)1.74 (0.04)1.90 (0.05)(1.81, 2.00)Reader 32023.97 (0.03)2.61 (0.03)1.36 (0.04)(1.29, 1.44)Internal morphologyReader 12273.92 (0.03)1.66 (0.03)2.26 (0.03)(2.20, 2.33)Reader 22293.65 (0.03)1.88 (0.03)1.77 (0.04)(1.69, 1.85)Reader 32023.97 (0.04)2.01 (0.04)1.96 (0.05)(1.85, 2.06)Degree of contrast enhancementReader 12273.77 (0.03)1.00 (0.03)2.77 (0.04)(2.69, 2.85)Reader 22293.58 (0.03)1.00 (0.03)2.58 (0.05)(2.49, 2.67)Reader 32023.90 (0.02)1.00 (0.02)2.90 (0.03)(2.84, 2.95)Gadopiclenol lesion visualization scores and number of lesions identified per patient were similar to those for gadobutrol.. 14.3 Visualization ofBody Lesions. Study included 304 patients presenting with known or suspectedenhancing abnormality(ies) and/or lesion(s) in at least one regionamong the head and neck, musculoskeletal system including extremities,and body including thorax, abdomen, and pelvis. Among the enrolledpatients, 278 had assessable pre-contrast and paired images with atleast one matching lesion for at least one reader. These patientshad mean age of 57 years (range: 21 years to 86 years), 59% werefemale, and 71% were White.Three readers assessed images of the headand neck, three other readers assessed images of the musculoskeletalsystem, and another three readers assessed other areas collectivelyreferred to as the body (thorax, abdomen, and pelvis). Lesion visualizationscores by reader in each anatomic region at patient-level as supportiveanalyses are summarized in Table 7.Table 7. Patient-Level Body Lesion Visualization Scores byReader and Anatomic Region, Paired vs. Pre-contrast in Patients ReceivingVueway 0.05 mmol/kg Intravenously LS: Least Squares; SE: Standard Error; CI: ConfidenceInterval.Only matching lesions are considered. The mixedmodels based on the full analysis set (N=278) include lesion visualizationfactor as dependent variable, patient as random factor, and MRImodality (Pre-contrast and Paired MRI), body regions, and MRI bodyregions as fixed factors.nLS Mean(SE)95% CIdifferencePairedPre-contrastDifferenceHead NeckBorder delineationReader 1153.71 (0.10)2.13 (0.10)1.58 (0.14)(1.30, 1.86)Reader 2193.53 (0.18)2.11 (0.18)1.42 (0.18)(1.06, 1.78)Reader 3133.92 (0.13)2.85 (0.13)1.08 (0.13)(0.82, 1.33)Internal morphologyReader 1153.80 (0.07)1.87 (0.07)1.93 (0.10)(1.74, 2.12)Reader 2193.74 (0.14)2.05 (0.14)1.68 (0.16)(1.37, 2.00)Reader 3133.92 (0.12)2.54 (0.12)1.38 (0.14)(1.10, 1.67)Degree of contrast enhancementReader 1153.60 (0.11)1.00 (0.11)2.60 (0.16)(2.29, 2.91)Reader 2193.68 (0.16)1.00 (0.16)2.68 (0.22)(2.22, 3.15)Reader 3133.92 (0.11)1.00 (0.11)2.92 (0.15)(2.61, 3.24)Musculoskeletal system(including extremities)Border delineationReader 1173.00 (0.10)2.06 (0.10)0.94 (0.13)(0.68, 1.20)Reader 2172.68 (0.20)2.44 (0.20)0.24 (0.19)(-0.15, 0.62)Reader 3212.81 (0.10)2.05 (0.10)0.76 (0.10)(0.56, 0.96)Internal morphologyReader 1173.00 (0.07)2.00 (0.07)1.00 (0.09)(0.82, 1.18)Reader 2173.94 (0.15)2.35 (0.15)1.59 (0.17)(1.25, 1.92)Reader 3212.90 (0.09)2.05 (0.09)0.86 (0.11)(0.64, 1.08)Degree of contrast enhancementReader 1172.82 (0.10)1.00 (0.10)1.82 (0.15)(1.53, 2.12)Reader 2173.33 (0.17)1.00 (0.17)2.33 (0.24)(1.847, 2.82)Reader 3213.06 (0.08)1.00 (0.08)2.06 (0.12)(1.82, 2.31)Body (thorax, abdomen, pelvis)Border delineationReader 12193.86 (0.03)2.28 (0.03)1.57 (0.04)(1.50, 1.64)Reader 21943.54 (0.06)3.15 (0.06)0.40 (0.06)(0.29, 0.51)Reader 32283.53 (0.03)1.69 (0.03)1.84 (0.03)(1.78, 1.90)Internal morphologyReader 12193.86 (0.02)2.00 (0.02)1.87 (0.03)(1.82, 1.92)Reader 21943.74 (0.05)3.41 (0.05)0.33 (0.05)(0.23, 0.43)Reader 32283.78 (0.03)1.60 (0.03)2.17 (0.03)(2.11, 2.24)Degree of contrast enhancementReader 12193.71 (0.03)1.00 (0.03)2.71 (0.04)(2.63, 2.79)Reader 21942.69 (0.05)1.00 (0.05)1.69 (0.07)(1.54, 1.83)Reader 32283.33 (0.03)1.00 (0.03)2.33 (0.44)(2.25, 2.40)Gadopiclenol lesion visualizationscores and number of lesions identified per patient were similar tothose for gadobutrol.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. The recommended dose for adult and pediatric patients aged years and older is 0.05 mmol/kg actual body weight (equivalent to 0.1 mL/kg) administered intravenously at approximately mL/sec. (2). The recommended dose for adult and pediatric patients aged years and older is 0.05 mmol/kg actual body weight (equivalent to 0.1 mL/kg) administered intravenously at approximately mL/sec. (2). 2.1 Recommended Dosage. The recommended dose of Vueway for adult and pediatric patients aged years and older is 0.05 mmol/kg actual body weight (equivalent to 0.1 mL/kg) administered intravenously at approximately mL/sec.. 2.2 Administration and Imaging Instructions. Use aseptic technique for all handling and administration of Vueway.Visually inspect Vueway for particulate matter and discoloration prior to administration. Do not use the solution if any particulate matter is present or the solution is discolored.Do not mix with other medications because of the potential for chemical incompatibility.Prime intravenous line before use.Administer Vueway as an intravenous bolus injection, manually or by compatible power injector. The recommended injection rate is approximately mL/second.Flush the intravenous line with 0.9% Sodium Chloride Injection, USP after the administration of Vueway.Contrast MRI can begin immediately following the injection of Vueway.. Use aseptic technique for all handling and administration of Vueway.. Visually inspect Vueway for particulate matter and discoloration prior to administration. Do not use the solution if any particulate matter is present or the solution is discolored.. Do not mix with other medications because of the potential for chemical incompatibility.. Prime intravenous line before use.. Administer Vueway as an intravenous bolus injection, manually or by compatible power injector. The recommended injection rate is approximately mL/second.. Flush the intravenous line with 0.9% Sodium Chloride Injection, USP after the administration of Vueway.. Contrast MRI can begin immediately following the injection of Vueway.. 2.3 Directionsfor Use of Single-Dose Vial and Pre-filled Syringe. VialDo not pierce the rubber stopper more than once.Aseptically draw up Vueway into disposable syringe and use immediately.If solidification occurs in the vial because of exposure to the cold, bring the vial of Vueway to room temperature before use and inspect that the solution is clear, colorless to yellow without any particulate matter and discoloration.Discard any unused portion.Pre-filled syringeRemove the tip cap of the syringe, screw the plunger rod and use immediately.All luer connections should be gently hand tightened without over tightening, to ensure secure connections and to prevent damage to the device.Pre-filled syringes must not be frozen. Frozen pre-filled syringes of Vueway should be discarded.Discard any unused portion.. Do not pierce the rubber stopper more than once.. Aseptically draw up Vueway into disposable syringe and use immediately.. If solidification occurs in the vial because of exposure to the cold, bring the vial of Vueway to room temperature before use and inspect that the solution is clear, colorless to yellow without any particulate matter and discoloration.. Discard any unused portion.. Remove the tip cap of the syringe, screw the plunger rod and use immediately.. All luer connections should be gently hand tightened without over tightening, to ensure secure connections and to prevent damage to the device.. Pre-filled syringes must not be frozen. Frozen pre-filled syringes of Vueway should be discarded.. Discard any unused portion.. 2.4 Directions for Use of Pharmacy Bulk Package. Do not use the Pharmacy Bulk Package for direct infusion.Perform the transfer of Vueway from the Pharmacy Bulk Package in an aseptic work area, such as laminar flow hood, using aseptic technique and suitable transfer device for filling empty syringes.Penetrate the closure only one time. Once the container closure is punctured, do not remove the Pharmacy Bulk Package from the aseptic work area.The Pharmacy Bulk Package is used with an appropriate transfer device for filling empty sterile syringes. Use each individual dose of Vueway promptly following withdrawal from the Pharmacy Bulk Package.Use the contents of the Pharmacy Bulk Package within 24 hours at room temperature after initial puncture.If solidification occurs in the vial because of exposure to the cold, bring the vial of Vueway to room temperature before use and inspect that the solution is clear, colorless to yellow without any particulate matter and discoloration.. Do not use the Pharmacy Bulk Package for direct infusion.. Perform the transfer of Vueway from the Pharmacy Bulk Package in an aseptic work area, such as laminar flow hood, using aseptic technique and suitable transfer device for filling empty syringes.. Penetrate the closure only one time. Once the container closure is punctured, do not remove the Pharmacy Bulk Package from the aseptic work area.. The Pharmacy Bulk Package is used with an appropriate transfer device for filling empty sterile syringes. Use each individual dose of Vueway promptly following withdrawal from the Pharmacy Bulk Package.. Use the contents of the Pharmacy Bulk Package within 24 hours at room temperature after initial puncture.. If solidification occurs in the vial because of exposure to the cold, bring the vial of Vueway to room temperature before use and inspect that the solution is clear, colorless to yellow without any particulate matter and discoloration.

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. Advise the patient to read the FDA-approved patient labeling (Medication Guide).Nephrogenic Systemic FibrosisInform the patient that Vueway may increase the risk for NSF among patients with impaired elimination of the drugs and that NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.Instruct the patients to contact their physician if they develop signs or symptoms of NSF following Vueway administration, such as burning, itching, swelling, scaling, hardening and tightening of the skin; red or dark patches on the skin; stiffness in joints with trouble moving, bending or straightening the arms, hands, legs or feet; pain in the hip bones or ribs; or muscle weakness [see Warnings and Precautions (5.1)].Gadolinium RetentionAdvise patients that gadolinium is retained for months or years in brain, bone, skin, and other organs following Vueway administration even in patients with normal renal function. The clinical consequences of retention are unknown. Retention depends on multiple factors and is greater following administration of linear GBCAs than following administration of macrocyclic GBCAs [see Warnings and Precautions (5.3)].Injection Site ReactionsInform the patient that Vueway may cause reactions along the venous injection site, such as mild and transient burning or pain or feeling of warmth or coldness at the injection site [see Warnings and Precautions (5.5)].PregnancyAdvise pregnant women of the potential risk of fetal exposure to Vueway [see Use in Specific Populations (8.1)].CL121A01Revised: 9/2022Manufactured forBracco Diagnostics Inc.Monroe Township, NJ 08831byLiebel-Flarsheim Company LLC,8800 Durant Road, Raleigh, North Carolina (NC) 27616-3104, USA.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. The Cmax and AUCinf of gadopiclenol increased proportionally over dosage range from 0.025 mmol/kg to 0.3 mmol/kg (0.5 times to times the recommended dosage). At the recommended dose, the mean (CV%) Cmax and AUCinf were 525 (13%) ug/mL and 569 (18%) ug.h/mL, respectively.DistributionAfter intravenous administration of Vueway, gadopiclenol is distributed in the extracellular fluids.The mean (CV%) volume of distribution of gadopiclenol at steady state is 13 (13%) L.Protein binding of gadopiclenol is <= 1.8% at clinically relevant concentrations.Following GBCA administration, gadolinium is present for months or years in brain, bone, skin, and other organs [see Warnings and Precautions (5.3)]. It is unknown whether the recommended dose of Vueway results in similar or different levels of gadolinium retention relative to those of other approved macrocyclic GBCAs at their recommended doses.EliminationThe mean (CV%) elimination half-life (t1/2) of gadopiclenol is 1.5 (14%) hour.The mean (CV%) total body clearance (CL) and renal clearance (CLr) of gadopiclenol are 100 (9.5%) mL/min and 81 (35%) mL/min, respectively. Metabolism Gadopiclenol is not metabolized. Excretion Gadopiclenol is mainly eliminated through the kidneys by glomerular filtration. Approximately 98% of the dose was recovered in urine within 48 hours after administration.Specific PopulationsNo clinically significant differences in the pharmacokinetics of gadopiclenol were observed based on sex.Pediatric PatientsThe pharmacokinetics of gadopiclenol for pediatric patients (2 to 17 years of age) were within range to those of adults (> 18 years of age) [see Dosage and Administration (2.1)].The pharmacokinetic parameters (median [range]) of gadopiclenol in pediatric patients are presented in Table 4.Table 4. Pharmacokinetic Parameters (Median [Range])a According to Age ClassesaAt the recommended dosage2-6 years7-11 years12-17 years>18 yearsCL (L/h/kg)0.12 [0.05; 0.28]0.10 [0.04; 0.24]0.08 [0.04; 0.20]0.08 [0.05; 0.14]t1/2 (h)1.29 [0.69; 3.38]1.48 [0.83; 3.20]1.77 [1.00; 3.57]1.82 [0.93; 3.68]AUCinf (ugoh/mL)403 [169; 964]478 [183; 1077]582 [267; 12901]590 [353; 937]C20 (ug/mL)236 [136; 387]260 [151; 401]286 [155; 441]296 [166; 485]Patients with Renal ImpairmentThe pharmacokinetic parameters (mean (%CV)) of gadopiclenol in patients with renal impairment are presented in Table 5.Table 5. Effect of Renal Impairment on the Pharmacokinetics of Gadopiclenola,b aFollowing administration of single gadopiclenol 0.1 mmol/kg dose (2 times the recommended dosage).beGFR: estimate of GFR based on an estimation equation and expressed in mL/min. To convert mL/min/1.73 m2 to mL/min, multiply by the individuals BSA and divide by 1.73.Normal (eGFR >= 90 mL/min)Mild (eGFR 60 to 90 mL/min)Moderate (eGFR 30 to 60 mL/min)Severe (eGFR 15 to 30 mL/min)AUCinf (ugoh/mL)1113 (24%)1711 (31%)2759 (28%)9671 (18%)CLr (mL/min)96 (10%)76 (23%)44 (25%)14 (26%)t1/2 (h)1.93.33.811.7In patients with mild or moderate renal impairment, more than 90% of the administered Vueway was recovered in urine within 48 hours. In patients with severely impaired renal function about 84% of the administered Vueway was recovered in urine within days.In patients with eGFR 15 mL/min, hemodialysis effectively removed gadopiclenol from plasma as the percentage of decrease in blood concentrations was 95 to 98% at the end of the first hemodialysis session and 100% after the third hemodialysis session [see Warnings and Precautions (5.1), Use in Specific Populations (8.6)].

PREGNANCY SECTION.

8.1 Pregnancy. Risk SummaryThere are no available data on Vueway use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. The available human data on GBCA exposure during pregnancy and adverse fetal outcomes are limited and inconclusive (see Data).In animal reproduction studies, there were no adverse developmental effects observed in rats or rabbits with intravenous administration of Vueway during organogenesis (see Data).Because of the potential risks of gadolinium to the fetus, use Vueway only if imaging is essential during pregnancy and cannot be delayed.The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20% respectively.DataHuman DataContrast enhancement is visualized in the placenta and fetal tissues after maternal GBCA administration.Cohort studies and case reports on exposure to GBCAs during pregnancy have not reported clear association between GBCAs and adverse effects in the exposed neonates. However, retrospective cohort study comparing pregnant women who had GBCA MRI to pregnant women who did not have an MRI reported higher occurrence of stillbirths and neonatal deaths in the group receiving GBCA MRI. Limitations of this study include lack of comparison with non-contrast MRI and lack of information about the maternal indication for MRI. Overall, these data preclude reliable evaluation of the potential risk of adverse fetal outcomes with the use of GBCAs in pregnancy.Animal DataGadolinium Retention: GBCAs administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least months. GBCAs administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one-month postnatal age.Reproductive Toxicology: Animal reproduction studies conducted with gadopiclenol showed some signs of maternal toxicity in rats at 10 mmol/kg and rabbits at mmol/kg (corresponding to 52 times and 57 times the recommended human dose, respectively). This maternal toxicity was characterized in both species by swelling, decreased activity, and lower gestation weight gain and food consumption.No effect on embryo-fetal development was observed in rats at 10 mmol/kg (corresponding to 52 times the recommended human dose). In rabbits, lower mean fetal body weight was observed at mmol/kg (corresponding to 57 times the recommended human dose) and this was attributed as consequence of the lower gestation weight gain.

SPL MEDGUIDE SECTION.

This Medication Guide has been approved by the U.S. Food and Drug Administration.Approved: 9/2022MEDICATION GUIDEVueway (VIEW-way)(gadopiclenol)injection, for intravenous useWhat is VuewayVueway is prescription medicine called gadolinium-based contrast agent (GBCA). Vueway, like other GBCAs, is injected into your vein and used with magnetic resonance imaging (MRI) scanner.An MRI exam with GBCA, including Vueway, helps your healthcare provider to see problems better than an MRI exam without GBCA.Your healthcare provider has reviewed your medical records and has determined that you would benefit from using GBCA with your MRI exam.What is the most important information should know about VuewayVueway contains metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin and other parts of your body for long time (several months to years).It is not known how gadolinium may affect you, but so far, studies have not found harmful effects in patients with normal kidneys.Rarely patients have reported pains, tiredness, and skin, muscle or bone ailments for long time, but these symptoms have not been directly linked to gadolinium.There are different GBCAs that can be used for your MRI exam. The amount of gadolinium that stays in the body is different for different gadolinium medicines. Gadolinium stays in the body more after gadodiamide than after gadoxetate disodium or gadobenate dimeglumine. Gadolinium stays in the body the least after, gadoterate meglumine, gadobutrol, gadoteridol, and gadopiclenol.People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from gadolinium staying in the body.Some people with kidney problems who get gadolinium medicines can develop condition with severe thickening of the skin, muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive Vueway.Do not receive Vueway if you have had severe allergic reaction to Vueway.Before receiving Vueway, tell your healthcare provider about all your medical conditions, including if you:have had any MRI procedures in the past where you received GBCA. Your healthcare provider may ask you for more information including the dates of these MRI procedures.are pregnant or plan to become pregnant. It is not known if Vueway can harm your unborn baby. Talk to your healthcare provider about the possible risks to an unborn baby if GBCA such as Vueway is received during pregnancy.have kidney problems, diabetes, or high blood pressure.have had an allergic reaction to dyes (contrast agents) including GBCAs.What are possible side effects of VuewaySee What is the most important information should know about VuewayAllergic reactions. Vueway can cause allergic reactions that can sometimes be serious. Your healthcare provider will monitor you closely for symptoms of an allergic reaction.The most common side effects of Vueway include: injection site pain, headache, nausea, injection site coldness, injection site warmth, dizziness, and localized swelling.These are not all the possible side effects of Vueway. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.General information about the safe and effective uses of Vueway.Medicines are sometimes prescribed for purposes other than those listed in Medication Guide. You can ask your healthcare provider for information about Vueway that is written for health professionals.What are the ingredients in VuewayActive ingredient: gadopiclenolInactive ingredients: tetraxetan; trometamol; hydrochloric acid or sodium hydroxide for pH adjustment; and water for injectionManufactured for Bracco Diagnostics Inc.by: Liebel-Flarsheim Company LLC, 8800 Durant Road, Raleigh, North Carolina (NC) 27616-3104, USADistributed by: Bracco Diagnostics Inc., 259 Prospect Plains Road, Monroe Township, New Jersey 08831, USAFor more information, go to www.imaging.bracco.com or call 800-257-5181.. Vueway is prescription medicine called gadolinium-based contrast agent (GBCA). Vueway, like other GBCAs, is injected into your vein and used with magnetic resonance imaging (MRI) scanner.. An MRI exam with GBCA, including Vueway, helps your healthcare provider to see problems better than an MRI exam without GBCA.. Your healthcare provider has reviewed your medical records and has determined that you would benefit from using GBCA with your MRI exam.. Vueway contains metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin and other parts of your body for long time (several months to years).. It is not known how gadolinium may affect you, but so far, studies have not found harmful effects in patients with normal kidneys.. Rarely patients have reported pains, tiredness, and skin, muscle or bone ailments for long time, but these symptoms have not been directly linked to gadolinium.. There are different GBCAs that can be used for your MRI exam. The amount of gadolinium that stays in the body is different for different gadolinium medicines. Gadolinium stays in the body more after gadodiamide than after gadoxetate disodium or gadobenate dimeglumine. Gadolinium stays in the body the least after, gadoterate meglumine, gadobutrol, gadoteridol, and gadopiclenol.. People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from gadolinium staying in the body.. Some people with kidney problems who get gadolinium medicines can develop condition with severe thickening of the skin, muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive Vueway.. have had any MRI procedures in the past where you received GBCA. Your healthcare provider may ask you for more information including the dates of these MRI procedures.. are pregnant or plan to become pregnant. It is not known if Vueway can harm your unborn baby. Talk to your healthcare provider about the possible risks to an unborn baby if GBCA such as Vueway is received during pregnancy.. have kidney problems, diabetes, or high blood pressure.. have had an allergic reaction to dyes (contrast agents) including GBCAs.. See What is the most important information should know about Vueway. Allergic reactions. Vueway can cause allergic reactions that can sometimes be serious. Your healthcare provider will monitor you closely for symptoms of an allergic reaction.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. Pregnancy: Use only if imaging is essential duringpregnancy and cannot be delayed. (8.1). 8.1 Pregnancy. Risk SummaryThere are no available data on Vueway use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. The available human data on GBCA exposure during pregnancy and adverse fetal outcomes are limited and inconclusive (see Data).In animal reproduction studies, there were no adverse developmental effects observed in rats or rabbits with intravenous administration of Vueway during organogenesis (see Data).Because of the potential risks of gadolinium to the fetus, use Vueway only if imaging is essential during pregnancy and cannot be delayed.The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20% respectively.DataHuman DataContrast enhancement is visualized in the placenta and fetal tissues after maternal GBCA administration.Cohort studies and case reports on exposure to GBCAs during pregnancy have not reported clear association between GBCAs and adverse effects in the exposed neonates. However, retrospective cohort study comparing pregnant women who had GBCA MRI to pregnant women who did not have an MRI reported higher occurrence of stillbirths and neonatal deaths in the group receiving GBCA MRI. Limitations of this study include lack of comparison with non-contrast MRI and lack of information about the maternal indication for MRI. Overall, these data preclude reliable evaluation of the potential risk of adverse fetal outcomes with the use of GBCAs in pregnancy.Animal DataGadolinium Retention: GBCAs administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least months. GBCAs administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one-month postnatal age.Reproductive Toxicology: Animal reproduction studies conducted with gadopiclenol showed some signs of maternal toxicity in rats at 10 mmol/kg and rabbits at mmol/kg (corresponding to 52 times and 57 times the recommended human dose, respectively). This maternal toxicity was characterized in both species by swelling, decreased activity, and lower gestation weight gain and food consumption.No effect on embryo-fetal development was observed in rats at 10 mmol/kg (corresponding to 52 times the recommended human dose). In rabbits, lower mean fetal body weight was observed at mmol/kg (corresponding to 57 times the recommended human dose) and this was attributed as consequence of the lower gestation weight gain.. 8.2 Lactation. Risk Summary There are no data on the presence of gadopiclenol in human milk,the effects on the breastfed infant, or the effects on milk production.However, published lactation data on other GBCAs indicate that 0.01%to 0.04% of the maternal gadolinium dose is excreted in breast milk.Additionally, there is limited GBCA gastrointestinal absorption inthe breast-fed infant. Gadopiclenol is present in rat milk. When adrug is present in animal milk, it is likely that the drug will bepresent in human milk (see Data). The developmental and health benefits of breastfeedingshould be considered along with the mothers clinical need for Vuewayand any potential adverse effects on the breastfed infant from Vuewayor from the underlying maternal condition.DataIn lactating ratsreceiving single intravenous injection of [153Gd]-gadopiclenol, 0.3% and 0.2% of the total administered radioactivitywas transferred to the pups via maternal milk at hours and 24 hoursafter administration, respectively. Furthermore, in nursing rat pups,oral absorption of gadopiclenol was 3.6%.. 8.4 Pediatric Use. The safety and effectiveness of Vueway foruse with MRI to detect and visualize lesions with abnormal vascularityin the CNS (brain, spine, and associated tissues), and the body (headand neck, thorax, abdomen, pelvis, and musculoskeletal system) havebeen established in pediatric patients aged years and older.Use of Vueway in this age groupis supported by evidence from adequate and well-controlled studiesin adults with additional pharmacokinetic and safety data from anopen-label, uncontrolled, multicenter, single dose study of Vueway(0.05 mmol/kg) in 80 pediatric patients aged to 17 years. The 80patients consisted of 60 patients who underwent CNS MRI and 20 patientswho underwent body MRI [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3)].The safety and effectiveness of Vueway havenot been established in pediatric patients younger than years ofage.. 8.5 Geriatric use. Of the total number of Vueway-treated patientsin clinical studies, 270 (26%) patients were 65 years of age and over,while 62 (6%) patients were 75 years of age and over. No overall differencesin safety or efficacy were observed between these subjects and youngersubjects.This drugis known to be substantially excreted by the kidney, and the riskof adverse reactions to this drug may be greater in patients withimpaired renal function. Because elderly patients are more likelyto have decreased renal function, it may be useful to monitor renalfunction.. 8.6 Renal impairment. In patients with renal impairment,the exposure of gadopiclenol is increased compared to patients withnormal renal function. This may increase the risk of adverse reactionssuch as nephrogenic systemic fibrosis (NSF). Avoid use of GBCAs amongthese patients unless the diagnostic information is essential andnot available with non-contrast MRI or other modalities. No doseadjustment of Vueway is recommended for patients with renal impairment.Vueway can be removed from the body by hemodialysis [see Warningsand Precautions (5.1, 5.3, 5.4) and Clinical Pharmacology (12.3)].

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs. Higher than recommended dosing or repeat dosing appear to increase the risk. (5.1)Hypersensitivity Reactions: Serious hypersensitivity reactions have occurred with GBCAs. Monitor patients closely for need of emergency cardiorespiratory support. (5.2)Gadolinium Retention: Gadolinium is retained for months or years in brain, bone, and other organs. (5.3). Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs. Higher than recommended dosing or repeat dosing appear to increase the risk. (5.1). Hypersensitivity Reactions: Serious hypersensitivity reactions have occurred with GBCAs. Monitor patients closely for need of emergency cardiorespiratory support. (5.2). Gadolinium Retention: Gadolinium is retained for months or years in brain, bone, and other organs. (5.3). 5.1 Nephrogenic SystemicFibrosis. Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities. The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR <30 mL/min/1.73 m2) as well as patients with acute kidney injury. The risk appears lower for patients with chronic, moderate kidney disease (GFR 30-59 mL/min/1.73 m2) and little, if any, for patients with chronic, mild kidney disease (GFR 60-89 mL/min/1.73 m2). NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. Report any diagnosis of NSF following Vueway administration to Bracco Diagnostics Inc. (1-800-257-5181) or FDA (1-800-FDA-1088 or www.fda.gov/medwatch).Screen patients for acute kidney injury and other conditions that may reduce renal function. Features of acute kidney injury consist of rapid (over hours to days) and usually reversible decrease in kidney function, commonly in the setting of surgery, severe infection, injury or drug-induced kidney toxicity. Serum creatinine levels and estimated GFR may not reliably assess renal function in the setting of acute kidney injury. For patients at risk for chronically reduced renal function (e.g., age >60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing.Among the factors that may increase the risk for NSF are repeated or higher than recommended doses of GBCA and the degree of renal impairment at the time of exposure. Record the specific GBCA and the dose administered to patient. For patients at highest risk for NSF, do not exceed the recommended Vueway dose and allow sufficient period of time for elimination of the drug prior to re-administration. For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of GBCA in order to enhance the contrast agents elimination [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. The usefulness of hemodialysis in the prevention of NSF is unknown.. 5.2 HypersensitivityReactions. With GBCAs, serious hypersensitivity reactions have occurred. In most cases, initial symptoms occurred within minutes of GBCA administration and resolved with prompt emergency treatment.Before Vueway administration, assess all patients for any history of reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for hypersensitivity reaction to Vueway.Vueway is contraindicated in patients with history of hypersensitivity reactions to Vueway [see Contraindications (4)].Administer Vueway only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation.During and following Vueway administration, observe patients for signs and symptoms of hypersensitivity reactions.. Before Vueway administration, assess all patients for any history of reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for hypersensitivity reaction to Vueway.. Vueway is contraindicated in patients with history of hypersensitivity reactions to Vueway [see Contraindications (4)].. Administer Vueway only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation.. During and following Vueway administration, observe patients for signs and symptoms of hypersensitivity reactions.. 5.3 Gadolinium Retention. Gadolinium is retained for months or years in several organs. The highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (e.g. brain, skin, kidney, liver, and spleen). The duration of retention also varies by tissue and is longest in bone. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, gadolinium retention varies among the linear agents with gadodiamide causing greater retention than other linear agents such as gadoxetate disodium and gadobenate dimeglumine. Retention is lowest and similar among the macrocyclic GBCAs such as gadoterate meglumine, gadobutrol, gadoteridol, and gadopiclenol.Consequences of gadolinium retention in the brain have not been established. Pathologic and clinical consequences of GBCA administration and retention in skin and other organs have been established in patients with impaired renal function [see Warnings and Precautions (5.1)]. There are rare reports of pathologic skin changes in patients with normal renal function. Adverse events involving multiple organ systems have been reported in patients with normal renal function without an established causal link to gadolinium.While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent when choosing GBCA for these patients. Minimize repetitive GBCA imaging studies, particularly closely spaced studies, when possible.. 5.4 Acute Kidney Injury. In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent. Do not exceed the recommended dose.. 5.5 Extravasation andInjection Site Reactions. Injection site reactions such as injection site pain have been reported in the clinical studies with Vueway [see Adverse Reactions (6.1)]. Extravasation during Vueway administration may result in tissue irritation [see Nonclinical Toxicology (13.2)]. Ensure catheter and venous patency before the injection of Vueway.. 5.6 Interference withVisualization of Lesions Visible with Non-Contrast MRI. As with any GBCA, Vueway may impair the visualization of lesions seen on non-contrast MRI. Therefore, caution should be exercised when Vueway MRI scans are interpreted without companion non-contrast MRI scan.